In conclusion, IDegAsp OD provides predictable, efficacious fasting and prandial glycemic control in insulin-naïve patients with T2DM in a single injection, while significantly reducing the risk of nocturnal-confirmed hypoglycemia compared with IGlar. This evidence concerns the gene INS and Hypoglycemia.